Combination Treatment with Verinurad and Allopurinol in… : Journal of the American Society of Nephrology
porter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia. Methods: In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dL, estimated glomerular filtration rate (eGFR) ≥25 mL/minute/1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) 30-5000 mg/g to one of five treatment arms: placebo, placebo + allopurinol 300 mg/day, verinurad 3 mg + allopurinol 300 mg/day, verinurad 7.5 mg + allopurinol 300 mg/day or verinurad 12 mg + allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary endpoint was the change in UACR from baseline to 34 weeks. Secondary endpoints were changes from baseline in UACR at week 60, and changes in serum urate and eGFR at weeks 34 and 60. Results: Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 mL/min/1.73m2, median UACR 217 mg/g) were enrolled. At 34 weeks; the geometric m